Exploring the role of the MAX gene in small cell lung cancer and other neuroendocrine tumors
Official title: Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
Funded at Fred Hutchinson Cancer Center · NIH-10811720 · Data updated 2026-11-12
This study is looking at how a gene called MAX helps prevent small cell lung cancer and other similar tumors from growing, and it hopes to find new ways to treat these cancers by understanding what happens when this gene is missing.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | May 1, 2020 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $527,348 |
| NIH project number | 5R01CA248762-06 |
| Project ID | NIH-10811720 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with small cell lung cancer or other neuroendocrine tumors.
✕Less likely to help
Patients with non-neuroendocrine tumors or those without a diagnosis of small cell lung cancer may not benefit from this research.
What this research studies
This research investigates how the MAX gene functions as a tumor suppressor in small cell lung cancer (SCLC) and other neuroendocrine tumors. By using advanced techniques like CRISPR to manipulate gene expression, the study aims to understand the biological effects of MAX deletion on tumor growth and stability. Patients may benefit from insights gained about the mechanisms of their cancer, potentially leading to new therapeutic strategies. The research will also analyze gene interactions and expressions to provide a comprehensive view of tumor behavior.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with small cell lung cancer and other neuroendocrine tumors.
How similar studies have gone: Previous research has shown promising results in understanding the role of tumor suppressor genes in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Eisenman, Robert Neil — Fred Hutchinson Cancer Center
- Study coordinator: Eisenman, Robert Neil
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.